78 related articles for article (PubMed ID: 21277347)
41. [Gene therapy and regenerative medicine for metabolic syndrome].
Sonoyama T; Sone M; Nakao K
Nihon Rinsho; 2011 Jan; 69 Suppl 1():716-20. PubMed ID: 21766687
[No Abstract] [Full Text] [Related]
42. Editorial: Toward Personalized Treatment for Acute Myeloid Leukemia.
Selheim F; Herfindal L
Curr Pharm Biotechnol; 2016; 17(1):4-5. PubMed ID: 26311133
[No Abstract] [Full Text] [Related]
43. The Translation Cycle: round and round in cycles is the only way forward for regenerative medicine.
Mason C; Manzotti E
Regen Med; 2010 Mar; 5(2):153-5. PubMed ID: 20210573
[No Abstract] [Full Text] [Related]
44. Guest editors Paolo Decuzzi & John P. Cooke lend expertise on special regenerative medicine issue.
Cooke JP; Decuzzi P
Methodist Debakey Cardiovasc J; 2013; 9(4):185. PubMed ID: 24298306
[No Abstract] [Full Text] [Related]
45. Acute Myeloid Leukemia: Introduction.
Hourigan CS
Semin Hematol; 2015 Jul; 52(3):149. PubMed ID: 26111461
[No Abstract] [Full Text] [Related]
46. Exciting times for the journal.
Dietrich WD
Ther Hypothermia Temp Manag; 2015 Jun; 5(2):61. PubMed ID: 26057855
[No Abstract] [Full Text] [Related]
47. Exciting Times in Acute Myeloid Leukemia.
Tallman MS
Semin Hematol; 2019 Apr; 56(2):83. PubMed ID: 30926094
[No Abstract] [Full Text] [Related]
48. Cell Stem Cell, one year on.
Sweet DJ
Cell Stem Cell; 2008 Jun; 2(6):509. PubMed ID: 18522837
[No Abstract] [Full Text] [Related]
49. Exciting Times.
Ende J
Med Clin North Am; 2023 Jan; 107(1):xv-xvi. PubMed ID: 36402503
[No Abstract] [Full Text] [Related]
50. Exciting new times.
Hancocks Obe S
Br Dent J; 2024 Mar; 236(5):357. PubMed ID: 38459288
[No Abstract] [Full Text] [Related]
51. Association of KIR2DS4 and its variant KIR1D with leukemia.
Giebel S; Nowak I; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Kyrcz-Krzemien S; Kusnierczyk P
Leukemia; 2008 Nov; 22(11):2129-30; discussion 2130-1. PubMed ID: 18463675
[No Abstract] [Full Text] [Related]
52. [Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons].
Cazzola M; Pedrazzoli P; Bergamaschi G; Buonanno C; Cuomo A; D'Uva R; Ponchio L; Rosti V; Zappone E; Ascari E
Haematologica; 1990; 75 Suppl 4():20-7. PubMed ID: 2127411
[No Abstract] [Full Text] [Related]
53. Exciting times for our field and the Journal.
Humphries RK
Exp Hematol; 2011 Mar; 39(3):271. PubMed ID: 21277347
[No Abstract] [Full Text] [Related]
54. Synthetic small interfering RNAs reduce bcr-abl gene expression in leukaemic cells of de novo Philadelphia(+) acute myeloid leukaemia.
Koldehoff M; Steckel NK; Beelen DW; Elmaagacli AH
Clin Exp Med; 2006 Mar; 6(1):45-7. PubMed ID: 16550344
[No Abstract] [Full Text] [Related]
55. [Pathophysiology and treatment of acute myeloid leukemia].
Naoe J
Rinsho Ketsueki; 2003 Apr; 44(4):219-26. PubMed ID: 12784654
[No Abstract] [Full Text] [Related]
56. Chronic myeloid leukemia: proving ground for cancer stem cells.
Daley GQ
Cell; 2004 Oct; 119(3):314-6. PubMed ID: 15507204
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
